NaN
0
0
Recent research and industry developments suggest psychedelics such as psilocybin, MDMA, DMT, and ketamine may treat mental health conditions by physically repairing and restructuring brain systems linked to trauma, stress, and depression - while regulatory approvals and new drug designs signal growing medical acceptance and commercialisation of psychedelic therapies.
0
2
0
0
Recent research and industry developments suggest psychedelics such as psilocybin, MDMA, DMT, and ketamine may treat mental health conditions by physically repairing and restructuring brain systems linked to trauma, stress, and depression - while regulatory approvals and new drug designs signal growing medical acceptance and commercialisation of psychedelic therapies.
0
2
A roundup of the current global psychedelic medicine landscape, contrasting the US's rapid, politically driven push to fast-track approvals and research funding with Europe's more cautious, evidence-based approach, while covering shared challenges around trial design, access equity, and commercialisation.
0
0
0
2
